Le Lézard
Classified in: Health
Subject: SVY

Global Transplant Complications Drug Development Pipeline Review 2018 Featuring Medeor Therapeutics, Amgen and Novartis


DUBLIN, Dec. 18, 2018 /PRNewswire/ --

The "Transplant Complications Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

This report Transplant Complications Drug Development Pipeline Review, 2018, provides an overview of the pipeline landscape for transplant complications. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), liver transplant rejection, kidney transplant rejection and lung transplant rejection and features dormant and discontinued products.

GVHD is a complication that can occur after a stem cell or bone marrow transplant and involves the newly transplanted donor cells attacking the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment consists of immunosuppressants. There are 125 products in development for GVHD.

Organ transplantation replaces an injured or diseased organ with a healthy one. Following a transplant, the immune system may consider the transplanted tissue as foreign and work against it. Patients can develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously.

These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses, blocking organ rejection and facilitating a successful transplant. There are 18 products in development for liver transplant rejection, 49 products in development for kidney transplant rejection and 12 products in development for lung transplant rejection.

Molecular targets acted on by products in development for transplantation complications include tyrosine kinases, caspases and chemokine receptors. Companies operating in this pipeline space include Medeor Therapeutics, Amgen and Novartis.

Scope

Reasons to buy

Key Topics Covered:

1 Introduction
1.1 Transplant Complications Report Coverage
1.2 Graft Versus Host Disease (GVHD) - Overview
1.3 Liver Transplant Rejection - Overview
1.4 Kidney Transplant Rejection - Overview
1.5 Lung Transplant Rejection - Overview

2 Therapeutics Development
2.1 Graft Versus Host Disease (GVHD)
2.2 Liver Transplant Rejection
2.3 Kidney Transplant Rejection
2.4 Lung Transplant Rejection

3 Therapeutics Assessment
3.1 Graft Versus Host Disease (GVHD)
3.2 Liver Transplant Rejection
3.3 Kidney Transplant Rejection
3.4 Lung Transplant Rejection

4 Companies Involved in Therapeutics Development
4.1 Graft Versus Host Disease (GVHD)
4.2 Liver Transplant Rejection
4.3 Kidney Transplant Rejection
4.4 Lung Transplant Rejection

5 Dormant Projects
5.1 Graft Versus Host Disease (GVHD)
5.2 Liver Transplant Rejection
5.3 Kidney Transplant Rejection
5.4 Lung Transplant Rejection

6 Discontinued Products
6.1 Graft Versus Host Disease (GVHD)
6.2 Liver Transplant Rejection
6.3 Kidney Transplant Rejection

7 Product Development Milestones
7.1 Graft Versus Host Disease (GVHD)
7.2 Liver Transplant Rejection
7.3 Kidney Transplant Rejection
7.4 Lung Transplant Rejection

8 Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/research/vzj6fp/global_transplant?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 15:20
Vayiz Unveils PTLC - Mark 1: Revolutionizing Medical Diagnostics with Pioneering AI Technology
Vayiz, an exciting new startup in innovative AI-driven medical imaging solutions, today announced the launch of its groundbreaking product, PTLC - Mark 1. This advanced medical diagnosis software utilizes state-of-the-art artificial intelligence to...

at 15:00
NBA LEGEND UDONIS HASLEM UNVEILS FORTY OG CANNABIS STRAIN
The Flowery, the leading name in the Florida medical cannabis industry renowned for its commitment to the highest quality and authentic experiences, proudly announces its unique collaboration with Udonis Haslem, a 3-time NBA Champion and legendary...

at 14:50
AMERICAN SKIN ASSOCIATION EARNS CANDID'S 2024 PLATINUM SEAL OF TRANSPARENCY AND CHARITY NAVIGATOR'S FOUR-STAR RATING
American Skin Association (ASA) is thrilled to announce that it has received Candid's eminent 2024 Platinum Seal of Transparency and the coveted Four-Star Rating from Charity Navigator. Candid (formerly Guidestar & Foundation Center) is the world's...

at 14:48
Prelude and Loyal: Collaborating to Extend Canine Lifespans
Loyal, the San Francisco-based company dedicated to improving the health and longevity of dogs, and Prelude, the leading animal health-focused electronic data capture (EDC) system for clinical research, are proud to announce their strategic...

at 14:45
Minister Ya'ara Saks highlights budget investments to boost research funding in Canada
The federal government recently delivered Budget 2024: Fairness for Every Generation.  It is a plan to build a Canada that works better for everyone, where younger generations can get ahead, where their hard work pays off, and where they can buy a...

at 14:21
Three new board members join the Rideau Hall Foundation
The Rideau Hall Foundation (RHF) is delighted to welcome to its board of directors three new members who will help shape the direction and increase the nation-building impact of the RHF's work:...

More news about Health...


News published on and distributed by: